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Supplementary Figure 1 
Patient R1 serum analysis and isolation and characterization of IOMA. 
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(a) Neutralizing activity of purified serum IgG from patient R1 against a panel of 18 cross-clade HIV-1 viruses. 
Median inhibitory concentration (IC50) of serum IgG indicated in red (1-50 μg/mL); orange (51-100 μg/mL); 
yellow (101-300 μg/mL); or white (>500 μg/mL). (b) Neutralizing activity of total R1 serum IgG versus 
gp140YU2-absorbed R1 serum IgG against two HIV-1 viruses. (c) Representative flow cytometry plots for single 
cell-sorted 2cc-specific IgG+ B cells, pre-gated on total lymphocytes and singlets. (d) ELISAs measuring the 
binding of IOMA to wild-type gp140YU2 (left) and to the CD4bs knockout gp140YU2 D368R (right). Black lines with 
solid dots represent positive control antibody 10-1074; black lines with empty dot represent negative control 
antibody mGO53; blue lines represent IOMA; the yellow line represents the CD4bs antibody b12. (e) Clonal 
members of IOMA. Mature IOMA sequences are indicated in red. A dot indicates amino acid identity; a dash 
indicates an unclear residue in a sequence. Heavy chain clonal members (top). Light chain clonal members 
(bottom). 
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Virus ID Clade* IC50 IC80 Virus ID Clade* IC50 IC80
6535.3 B >50 >50 MS208.A1 A 3.732 44.580
QH0692.42 B 12.890 >50 Q23.17 A 0.833 3.309
SC422661.8 B 17.346 >50 Q461.e2 A >50 >50
PVO.4 B 0.490 1.776 Q769.d22 A 1.363 8.114
TRO.11 B 0.539 1.948 Q259.d2.17 A >50 >50
AC10.0.29 B >50 >50 Q842.d12 A 2.882 19.480
RHPA4259.7 B 9.564 >50 3415.v1.c1 A 0.710 4.166
THRO4156.18 B 29.741 >50 3365.v2.c2 A 4.986 >50
REJO4541.67 B >50 >50 0260.v5.c36 A 1.587 5.887
TRJO4551.58 B 11.703 >50
WITO4160.33 B 3.259 26.793 191955_A11 A (T/F) >50 >50
CAAN5342.A2 B 1.709 6.215 191084 B7-19 A (T/F) 10.737 >50
9004SS_A3_4 A (T/F) >50 >50
WEAU_d15_410_787 B (T/F) 3.019 39.304
1006_11_C3_1601 B (T/F) 0.289 1.553 T257-31 CRF02_AG >50 >50
1054_07_TC4_1499 B (T/F) 2.209 7.665 928-28 CRF02_AG >50 >50
1056_10_TA11_1826 B (T/F) 2.065 9.870  263-8 CRF02_AG 0.827 6.123
1012_11_TC21_3257 B (T/F) 0.347 1.253 T250-4 CRF02_AG >50 >50
6240_08_TA5_4622 B (T/F) 3.978 16.733 T251-18 CRF02_AG >50 >50
6244_13_B5_4576 B (T/F) 0.564 2.686 T278-50 CRF02_AG >50 >50
62357_14_D3_4589 B (T/F) 11.223 >50 T255-34 CRF02_AG >50 >50
SC05_8C11_2344 B (T/F) 1.465 5.589 211-9 CRF02_AG >50 >50
 235-47 CRF02_AG 0.159 0.623
Du156.12 C >50 >50
Du172.17 C >50 >50 620345.c01 CRF01_AE >50 >50
Du422.1 C >50 >50 CNE8 CRF01_AE >50 >50
ZM197M.PB7 C >50 >50 C1080.c03 CRF01_AE 15.291 >50
ZM214M.PL15 C 1.735 10.509 R2184.c04 CRF01_AE >50 >50
ZM233M.PB6 C >50 >50 R1166.c01 CRF01_AE 8.409 39.033
ZM249M.PL1 C >50 >50 C2101.c01 CRF01_AE 1.519 9.150
ZM53M.PB12 C 2.316 15.303 C3347.c11 CRF01_AE 0.097 0.440
ZM109F.PB4 C >50 >50 C4118.c09 CRF01_AE 7.096 >50
ZM135M.PL10a C >50 >50 CNE5 CRF01_AE >50 >50
CAP45.2.00.G3 C >50 >50 BJOX009000.02.4 CRF01_AE >50 >50
CAP210.2.00.E8 C >50 >50
HIV-001428-2.42 C >50 >50 BJOX015000.11.5 CRF01_AE (T/F) >50 >50
HIV-0013095-2.11 C 0.144 1.699 BJOX010000.06.2 CRF01_AE (T/F) >50 >50
HIV-16055-2.3 C >50 >50 BJOX025000.01.1 CRF01_AE (T/F) 1.468 28.723
HIV-16845-2.22 C >50 >50 BJOX028000.10.3 CRF01_AE (T/F) 20.540 38.852
Ce1086_B2 C (T/F) 0.556 8.351 X1193_c1 G >50 >50
Ce0393_C3 C (T/F) 14.803 >50 P0402_c2_11 G 16.024 >50
Ce1176_A3 C (T/F) 2.961 12.584 X1254_c3 G >50 >50
Ce2010_F5 C (T/F) 20.362 >50 X2088_c9 G
Ce0682_E4 C (T/F) 1.155 16.081 X2131_C1_B5 G >50 >50
Ce1172_H1 C (T/F) >50 >50 P1981_C5_3 G >50 >50
Ce2060_G9 C (T/F) >50 >50 X1632_S2_B10 G 0.641 5.105
Ce703010054_2A2 C (T/F) >50 >50
BF1266.431a C (T/F) 28.336 >50 3016.v5.c45 D >50 >50
246F C1G C (T/F) >50 >50 A07412M1.vrc12 D 8.447 >50
249M B10 C (T/F) 18.130 >50 231965.c01 D >50 >50
ZM247v1(Rev-) C (T/F) >50 >50 231966.c02 D 2.566 43.623
7030102001E5(Rev-) C (T/F) 13.298 46.729
1394C9G1(Rev-) C (T/F) 0.211 1.264 191821_E6_1 D (T/F) >50 >50
Ce704809221_1B3 C (T/F) 2.490 21.352
3817.v2.c59 CD 14.208 >50
CNE19 BC >50 >50 6480.v4.c25 CD >50 >50
CNE20 BC 0.044 0.368 6952.v1.c20 CD >50 >50
CNE21 BC 1.062 20.087 6811.v7.c18 CD >50 >50
CNE17 BC >50 >50 89-F1_2_25 CD >50 >50
CNE30 BC 8.291 46.591
CNE52 BC >50 >50 3301.v1.c24 AC 34.886 >50
CNE53 BC 0.127 0.769 6041.v3.c23 AC <0.023 0.082
CNE58 BC >50 >50 6540.v4.c1 AC >50 >50
6545.v4.c1 AC >50 >50
0815.v3.c3 ACD >50 >50
3103.v3.c10 ACD >50 >50
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Supplementary Figure 2 
Neutralizing activity of IOMA. 
Top, Clade-specific neutralizing activity of IOMA against a 118-virus panel. Geometric mean IC50 value 
including non-neutralized strains is indicated for each set of viruses by a red line; the green line indicates the 
geometric mean IC50 value calculated for only neutralized strains. The number of neutralized and total strains 
evaluated for each clade are indicated at the top of the panel. Bottom, Neutralizing activity of IOMA against a 
118-virus panel. IC50 and IC80 values (μg/mL) are indicated for each virus. Fields in red indicate neutralization. 
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Supplementary Figure 3 
Sequence alignment of CD4-mimetic bNAbs. 
(a) Heavy chains. (b) Light chains. (c) Dendrogram showing relation of VH1-2 (black) and VH1-46 (red) CD4bs 
bNAbs. The dendrogram was calculated based on nucleotide sequence similarity of their aligned HC V gene 
segments. Scale bar represents 20% nucleotide substitutions per site. 
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Supplementary Figure 4 
Characterization of BG505 SOSIP.664 protein used for crystallization. 
Size exclusion chromatography (SEC) profile showing migration of the BG505 SOSIP.664 used for incubation 
with IOMA and 10-1074 Fabs to generate samples for crystallization. Inset shows SDS-PAGE analysis under 
non-reducing conditions of SEC fractions. SEC fractions 7-8 (blue) (larger apparent molecular mass; likely 
more glycosylated) were used for the 3.9Å IOMA–10-1074–BG505 structure and fractions 11-12 (smaller 
apparent molecular mass; likely less glycosylated) were used for the 3.5Å IOMA–10-1074–BG505 structure 
(Table 1). 
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Supplementary Figure 5 
Glycans at individual BG505 SOSIP.664 PNGSs (N88gp120–N160gp120). 
Electron density (contoured at 0.8) from 2Fo-Fc maps calculated with model phases (labeled as 2Fo) or 
composite annealed omit maps calculated with phases in which the model was omitted to reduce model bias 
(Adams, P. D. et al. Acta Crystallogr D Biol Crystallogr 66, 213-221, 2010) (labeled as Omit) shown for PNGSs 
in the 3.9Å and the 3.5Å IOMA–10-1074–BG505 structures (Table 1). Glycan residues built into the electron 
density are shown as colored sticks (fucose, red; GlcNAc, blue; mannose, green; galactose, yellow; sialic acid, 
purple). We identified complex-type N-glycans primarily through the presence of electron density for a core 
fucose residue. Although the structures were extensively refined (see Methods), coordinates for glycans in our 
structures should be regarded as approximate: the glycan density was sometimes ambiguous, as expected 
given the large degree of glycan heterogeneity in HIV-1 Env, one of the most heavily glycosylated proteins 
known (Doores, K. J. FEBS J 282, 4679-4691, 2015). (b) Schematic versions of crystallographically-identified 
BG505 SOSIP.664 glycans  (fucose, red triangle; GlcNAc, blue square; mannose, green circle; galactose, 
yellow circle; sialic acid, purple diamond) shown in panel a (labeled as 3.9Å and 3.5Å) compared with glycans 
from the 4.2Å EM structure of a natively-glycosylated JR-FL (non-SOSIP) Env (Lee, J. H., Ozorowski, G. & 
Ward, A. B. Science 351, 1043-1048, 2016), the 3.7Å crystal structure of a high mannose-only fully- but not 
natively-glycosylated BG505 SOSIP.664 (Stewart-Jones, G. B. E. et al. Cell 165, 813-826, 2016), and a mass 
spectroscopy analysis of natively-glycosylated BG505 SOSIP.664 (Behrens, A. J. et al. Cell Reports 14, 2695-
2706, 2016). Not all glycan species identified at each PNGS by mass spectroscopy (Behrens, A. J. et al. Cell 
Reports 14, 2695-2706, 2016) are shown; the major species are depicted in this figure except at PNGSs in 
which it appears that our crystals contained a subset of BG505 SOSIP.664 protein with underrepresented 
glycan species (see text). Although the BG505 SOSIP.664 construct (Sanders, R. W. et al. PLoS Pathog 9, 
e1003618, 2013) was used both for our structures and the mass spectrometry analysis (Behrens, A. J. et al. 
Cell Reports 14, 2695-2706, 2016), some differences in glycans at individual PNGSs between the mass 
spectrometry study and our structures might be expected if the crystals preferentially incorporated a subset of 
the glycosylation states within the BG505 protein. 
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Supplementary Figure 6 
Glycans at individual BG505 SOSIP.664 PNGSs (N197gp120–N295gp120). 
Electron density (contoured at 0.8) from 2Fo-Fc maps calculated with model phases (labeled as 2Fo) or 
composite annealed omit maps calculated with phases in which the model was omitted to reduce model bias 
(Adams, P. D. et al. Acta Crystallogr D Biol Crystallogr 66, 213-221, 2010) (labeled as Omit) shown for PNGSs 
in the 3.9Å and the 3.5Å IOMA–10-1074–BG505 structures (Table 1). Glycan residues built into the electron 
density are shown as colored sticks (fucose, red; GlcNAc, blue; mannose, green; galactose, yellow; sialic acid, 
purple). We identified complex-type N-glycans primarily through the presence of electron density for a core 
fucose residue. Although the structures were extensively refined (see Methods), coordinates for glycans in our 
structures should be regarded as approximate: the glycan density was sometimes ambiguous, as expected 
given the large degree of glycan heterogeneity in HIV-1 Env, one of the most heavily glycosylated proteins 
known (Doores, K. J. FEBS J 282, 4679-4691, 2015). (b) Schematic versions of crystallographically-identified 
BG505 SOSIP.664 glycans  (fucose, red triangle; GlcNAc, blue square; mannose, green circle; galactose, 
yellow circle; sialic acid, purple diamond) shown in panel a (labeled as 3.9Å and 3.5Å) compared with glycans 
from the 4.2Å EM structure of a natively-glycosylated JR-FL (non-SOSIP) Env (Lee, J. H., Ozorowski, G. & 
Ward, A. B. Science 351, 1043-1048, 2016), the 3.7Å crystal structure of a high mannose-only fully- but not 
natively-glycosylated BG505 SOSIP.664 (Stewart-Jones, G. B. E. et al. Cell 165, 813-826, 2016), and a mass 
spectroscopy analysis of natively-glycosylated BG505 SOSIP.664 (Behrens, A. J. et al. Cell Reports 14, 2695-
2706, 2016). Not all glycan species identified at each PNGS by mass spectroscopy (Behrens, A. J. et al. Cell 
Reports 14, 2695-2706, 2016) are shown; the major species are depicted in this figure except at PNGSs in 
which it appears that our crystals contained a subset of BG505 SOSIP.664 protein with underrepresented 
glycan species (see text). Although the BG505 SOSIP.664 construct (Sanders, R. W. et al. PLoS Pathog 9, 
e1003618, 2013) was used both for our structures and the mass spectrometry analysis (Behrens, A. J. et al. 
Cell Reports 14, 2695-2706, 2016), some differences in glycans at individual PNGSs between the mass 
spectrometry study and our structures might be expected if the crystals preferentially incorporated a subset of 
the glycosylation states within the BG505 protein. 
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Supplementary Figure 7 
Glycans at individual BG505 SOSIP.664 PNGSs (N301gp120–N363gp120). 
Electron density (contoured at 0.8) from 2Fo-Fc maps calculated with model phases (labeled as 2Fo) or 
composite annealed omit maps calculated with phases in which the model was omitted to reduce model bias 
(Adams, P. D. et al. Acta Crystallogr D Biol Crystallogr 66, 213-221, 2010) (labeled as Omit) shown for PNGSs 
in the 3.9Å and the 3.5Å IOMA–10-1074–BG505 structures (Table 1). Glycan residues built into the electron 
density are shown as colored sticks (fucose, red; GlcNAc, blue; mannose, green; galactose, yellow; sialic acid, 
purple). We identified complex-type N-glycans primarily through the presence of electron density for a core 
fucose residue. Although the structures were extensively refined (see Methods), coordinates for glycans in our 
structures should be regarded as approximate: the glycan density was sometimes ambiguous, as expected 
given the large degree of glycan heterogeneity in HIV-1 Env, one of the most heavily glycosylated proteins 
known (Doores, K. J. FEBS J 282, 4679-4691, 2015). (b) Schematic versions of crystallographically-identified 
BG505 SOSIP.664 glycans  (fucose, red triangle; GlcNAc, blue square; mannose, green circle; galactose, 
yellow circle; sialic acid, purple diamond) shown in panel a (labeled as 3.9Å and 3.5Å) compared with glycans 
from the 4.2Å EM structure of a natively-glycosylated JR-FL (non-SOSIP) Env (Lee, J. H., Ozorowski, G. & 
Ward, A. B. Science 351, 1043-1048, 2016), the 3.7Å crystal structure of a high mannose-only fully- but not 
natively-glycosylated BG505 SOSIP.664 (Stewart-Jones, G. B. E. et al. Cell 165, 813-826, 2016), and a mass 
spectroscopy analysis of natively-glycosylated BG505 SOSIP.664 (Behrens, A. J. et al. Cell Reports 14, 2695-
2706, 2016). Not all glycan species identified at each PNGS by mass spectroscopy (Behrens, A. J. et al. Cell 
Reports 14, 2695-2706, 2016) are shown; the major species are depicted in this figure except at PNGSs in 
which it appears that our crystals contained a subset of BG505 SOSIP.664 protein with underrepresented 
glycan species (see text). Although the BG505 SOSIP.664 construct (Sanders, R. W. et al. PLoS Pathog 9, 
e1003618, 2013) was used both for our structures and the mass spectrometry analysis (Behrens, A. J. et al. 
Cell Reports 14, 2695-2706, 2016), some differences in glycans at individual PNGSs between the mass 
spectrometry study and our structures might be expected if the crystals preferentially incorporated a subset of 
the glycosylation states within the BG505 protein. 
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Supplementary Figure 8 
Glycans at individual BG505 SOSIP.664 PNGSs (N386gp120–N637gp41). 
Electron density (contoured at 0.8) from 2Fo-Fc maps calculated with model phases (labeled as 2Fo) or 
composite annealed omit maps calculated with phases in which the model was omitted to reduce model bias 
(Adams, P. D. et al. Acta Crystallogr D Biol Crystallogr 66, 213-221, 2010) (labeled as Omit) shown for PNGSs 
in the 3.9Å and the 3.5Å IOMA–10-1074–BG505 structures (Table 1). Glycan residues built into the electron 
density are shown as colored sticks (fucose, red; GlcNAc, blue; mannose, green; galactose, yellow; sialic acid, 
purple). We identified complex-type N-glycans primarily through the presence of electron density for a core 
fucose residue. Although the structures were extensively refined (see Methods), coordinates for glycans in our 
structures should be regarded as approximate: the glycan density was sometimes ambiguous, as expected 
given the large degree of glycan heterogeneity in HIV-1 Env, one of the most heavily glycosylated proteins 
known (Doores, K. J. FEBS J 282, 4679-4691, 2015). (b) Schematic versions of crystallographically-identified 
BG505 SOSIP.664 glycans  (fucose, red triangle; GlcNAc, blue square; mannose, green circle; galactose, 
yellow circle; sialic acid, purple diamond) shown in panel a (labeled as 3.9Å and 3.5Å) compared with glycans 
from the 4.2Å EM structure of a natively-glycosylated JR-FL (non-SOSIP) Env (Lee, J. H., Ozorowski, G. & 
Ward, A. B. Science 351, 1043-1048, 2016), the 3.7Å crystal structure of a high mannose-only fully- but not 
natively-glycosylated BG505 SOSIP.664 (Stewart-Jones, G. B. E. et al. Cell 165, 813-826, 2016), and a mass 
spectroscopy analysis of natively-glycosylated BG505 SOSIP.664 (Behrens, A. J. et al. Cell Reports 14, 2695-
2706, 2016). Not all glycan species identified at each PNGS by mass spectroscopy (Behrens, A. J. et al. Cell 
Reports 14, 2695-2706, 2016) are shown; the major species are depicted in this figure except at PNGSs in 
which it appears that our crystals contained a subset of BG505 SOSIP.664 protein with underrepresented 
glycan species (see text). Although the BG505 SOSIP.664 construct (Sanders, R. W. et al. PLoS Pathog 9, 
e1003618, 2013) was used both for our structures and the mass spectrometry analysis (Behrens, A. J. et al. 
Cell Reports 14, 2695-2706, 2016), some differences in glycans at individual PNGSs between the mass 
spectrometry study and our structures might be expected if the crystals preferentially incorporated a subset of 
the glycosylation states within the BG505 protein. 
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Supplementary Figure 9 
Effects of glycans on neutralization potencies of 10-1074 and IOMA. 
(a) Effects of an intact PNGS at N156gp120 on PGT121-family bNAbs. Geometric mean IC50s (µg/mL) of 10-
1074, PGT122, and PGT121 were calculated for HIV-1 strains with or without a PNGS at N156gp120. Only 
strains containing a PNGS at N332gp120 were included in this analysis. Mean IC50s are calculated treating >50 
µg/mL values as 50 µg/mL. PGT122 was ~2-fold more potent against strains including the N156gp120 PNGS, 
whereas 10-1074 showed ~4-fold greater potency against viral strains lacking the N156gp120 PNGS. PGT121 
also was more potent against strains lacking PNGS N156gp120. PGT122 has CDRL3 residue 95RLC, while 10-
1074 and PGT121 have Ser and Val at position 95LC, respectively. IC50 values are those reported in the 
following references: Mouquet, H. et al. Proc Natl Acad Sci USA 109, E3268-3277, 2012; Sok, D. et 
al. Science Translational Medicine 6, 236ra263, 2014; Walker, L. M. et al. Nature 477, 466–470, 
2011; Ferguson, A. L. et al. PLoS One 8, e80562, 2013; Huang, J. et al. Nature 515, 138-142, 2014. (b) 
Effects of glycan deletions at N137gp120, N156gp120, and N301gp120 on 10-1074 neutralization. In vitro 
neutralization assays were conducted with HIV-1YU2 pseudoviruses that included all glycans (listed as YU2), 
had introduced mutations to remove the N137gp120 glycan (YU2 N137S), the N156gp120 glycan (YU2 N156K), 
the N301gp120 glycan (YU2 N301S), or included all glycans in a high mannose form (YU2 Kif). (c,d) Comparison 
of glycosylation deletions on neutralization by IOMA and VRC01-class bNAbs (VRC01 and NIH45-46). In vitro 
neutralization assays were conducted with HIV-1YU2 pseudoviruses that included all glycans (listed as YU2), 
had introduced mutations to remove the N276gp120 glycan (YU2 N276K), the N197gp120 glycan (YU2 N197K), or 
included all glycans in a high mannose form (YU2 Kif). Removal of glycans or conversion to high-mannose-
only glycans had no effect (PNGS N197gp120) or increased IOMA’s neutralization potency by ~4-fold (PNGS 
N276gp120 and high-mannose-only glycans). For VRC01-class bNAbs, the same changes produced ~20-fold 
increased potency (PNGS N197gp120), ~4-11–fold increased potency (PNGS N276gp120), or ~2-fold increased 
potency (high-mannose-only glycans). 
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Supplementary Figure 10 
Comparisons of IOMA, VH1-2/VRC01-class, and VH1-46-class bNAbs. 
(a) Rotation angle and translation distance of VH domains of VH1-2 and VH1-46 CD4bs bNAbs in complex with 
Env (gp120 or trimer) relative to CD4 in complex with HxBc2 gp120 (PDB code 1GC1). Data points for 
complexes of VRC01-like bNAbs are shown as blue squares; complexes of 8ANC131-like bNAbs are shown 
as red diamonds; IOMA is shown as a purple square; VRC01 is shown as a blue circle. (b) Interactions of Env 
residue D368gp120 with IOMA residue R71HC and indicated bNAbs and with CD4 residue R59CD4. Black dashed 
lines indicate potential hydrogen bonds; red dashed lines indicate potential hydrogen bonds with non-ideal 
geometry. (c) Interactions of the CD4-binding loop in gp120 with CDRH2 of IOMA and indicated bNAbs and 
with the C” strand of CD4. Black dashed lines indicate potential hydrogen bonds; gray dashed lines indicate 
potential hydrogen bonds with non-ideal geometry. (d) IOMA’s interaction with N-glycan attached to N363gp120. 
R82BHC interacts with the core pentasaccharide of the N363gp120 glycan. Top: 2Fo-Fc electron density map 
(contoured at 0.8) superimposed over coordinates (glycans colored as in Supplementary Figs. 5–8). Bottom: 
coordinates alone. 
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Supplementary Note 
Sequence alignment of IOMA, VRC01, and 8ANC131 HCs and LCs with their respective germline V gene
segment sequences. 
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